Your browser doesn't support javascript.
loading
The economic impact of anastomotic leak after colorectal cancer surgery.
Flor-Lorente, Blas; Noguera-Aguilar, José Francisco; Delgado-Rivilla, Salvadora; García-González, José María; Rodriguez-Martín, Marcos; Salinas-Ortega, Laura; Casado, Miguel Ángel; Álvarez, María.
Afiliación
  • Flor-Lorente B; Colorectal Surgery Unit. Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Noguera-Aguilar JF; Colorectal Surgery Unit. Complejo Hospitalario y Universitario A Coruña, A Coruña, Spain.
  • Delgado-Rivilla S; Colorectal Surgery Unit, Hospital Universitario Mutua de Tarrassa, Barcelona, Spain.
  • García-González JM; Colorectal Surgery Unit, Hospital Universitario Cruces, Bilbao, Spain.
  • Rodriguez-Martín M; Colorectal Surgery Unit, Hospital Beata María Ana, Madrid, Spain.
  • Salinas-Ortega L; Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
  • Casado MÁ; Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
  • Álvarez M; Health Economics & Outcomes Research Unit (Medtronic Ibérica, S.A.), Madrid, Spain. maria.alvarez.orozco@medtronic.com.
Health Econ Rev ; 13(1): 12, 2023 Feb 16.
Article en En | MEDLINE | ID: mdl-36795234
ABSTRACT

OBJECTIVE:

To determine the economic impact of the incremental consumption of resources for the diagnosis and treatment of anastomotic leak (AL) in patients after resection with anastomosis for colorectal cancer compared to patients without AL on the Spanish health system.

METHOD:

This study included a literature review with parameters validated by experts and the development of a cost analysis model to estimate the incremental resource consumption of patients with AL versus those without. The patients were divided into three groups 1) colon cancer (CC) with resection, anastomosis and AL; 2) rectal cancer (RC) with resection, anastomosis without protective stoma and AL; and 3) RC with resection, anastomosis with protective stoma and AL.

RESULTS:

The average total incremental cost per patient was €38,819 and €32,599 for CC and RC, respectively. The cost of AL diagnosis per patient was €1018 (CC) and €1030 (RC). The cost of AL treatment per patient in Group 1 ranged from €13,753 (type B) to €44,985 (type C + stoma), that in Group 2 ranged from €7348 (type A) to €44,398 (type C + stoma), and that in Group 3 ranged from €6197 (type A) to €34,414 (type C). Hospital stays represented the highest cost for all groups. In RC, protective stoma was found to minimize the economic consequences of AL.

CONCLUSIONS:

The appearance of AL generates a considerable increase in the consumption of health resources, mainly due to an increase in hospital stays. The more complex the AL, the higher the cost associated with its treatment. INTEREST OF THE STUDY it is the first cost-analysis study of AL after CR surgery based on prospective, observational and multicenter studies, with a clear, accepted and uniform definition of AL and estimated over a period of 30 days.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Health_economic_evaluation Idioma: En Revista: Health Econ Rev Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Health_economic_evaluation Idioma: En Revista: Health Econ Rev Año: 2023 Tipo del documento: Article País de afiliación: España